{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:59:33Z","timestamp":1785189573884,"version":"3.55.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX005595"],"award-info":[{"award-number":["I01BX005595"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.canlet.2026.218533","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:35:00Z","timestamp":1776900900000},"page":"218533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Malignant ascites as an immune organ and implications for cancer immunotherapy"],"prefix":"10.1016","volume":"651","author":[{"given":"Dmitry D.","family":"Basov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia E.","family":"Metropulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayatullah G.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4355-6597","authenticated-orcid":false,"given":"Daniel R.","family":"Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218533_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with malignant ascites: a retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12029-025-01332-7","article-title":"Does malignant ascites define prognosis in gastric cancer with peritoneal spread? A systematic review and meta-analysis","volume":"56","author":"de Moraes","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1390426","article-title":"Research progress and treatment status of malignant ascites","volume":"14","author":"He","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/ajg.2018.18","article-title":"Development and validation of a patient-reported outcome measurement for symptom assessment in cirrhotic ascites","volume":"113","author":"Neijenhuis","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.canlet.2026.218533_bib6","first-page":"231","article-title":"The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer","volume":"1","author":"Meyer","year":"2016","journal-title":"Expert Rev Qual Life Cancer Care"},{"key":"10.1016\/j.canlet.2026.218533_bib7","first-page":"474","article-title":"Malignant ascites: demographics, therapeutic efficacy and predictors of survival","volume":"6","author":"Mackey","year":"1996","journal-title":"Can. J. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib8","series-title":"Paracentesis. StatPearls","author":"Kurapati","year":"2025"},{"key":"10.1016\/j.canlet.2026.218533_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082383","article-title":"Immunotherapy for peritoneal carcinomatosis: challenges and prospective outcomes","volume":"15","author":"Ornella","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218533_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004001","article-title":"Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers","volume":"10","author":"Fuca","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005345","article-title":"Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice","volume":"10","author":"Kucukkose","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103089","article-title":"Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer","volume":"143","author":"de Torres","year":"2026","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218533_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004749","article-title":"Resistance to systemic immune checkpoint inhibition in the peritoneal niche","volume":"10","author":"Chia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17081280","article-title":"Microbial and immune landscape of malignant ascites: insights from Gut, bladder, and ascitic fluid analyses","volume":"17","author":"Yun","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218533_bib15","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.0804324","article-title":"Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response","volume":"183","author":"Ruddle","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2007.06.009","article-title":"Plasticity and heterogeneity of lymphoid organs. What are the criteria to call a lymphoid organ primary, secondary or tertiary?","volume":"112","author":"Pabst","year":"2007","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.canlet.2026.218533_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s10147-020-01810-x","article-title":"Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden","volume":"26","author":"Suzuki","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13030834","article-title":"The efficacy and safety of nivolumab plus mFOLFOX6 in gastric cancer with severe peritoneal metastasis","volume":"13","author":"Nakayama","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218533_bib19","article-title":"Association between the presence of malignant ascites and survival outcomes of gastric cancer patients treated with nivolumab plus chemotherapy","volume":"43","author":"Lee","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib20","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high Microsatellite Instability\/Mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label Study of pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib23","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218533_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-018-0342-x","article-title":"Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib25","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e14576","article-title":"Outcomes of peritoneal metastases in mismatch repair deficient (dMMR) cancers treated with immune checkpoint inhibitors and variables associated with response","volume":"41","author":"Mosalem","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib27","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1186\/s12885-025-14206-9","article-title":"Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis","volume":"25","author":"Ma","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-022-04479-3","article-title":"Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review","volume":"90","author":"Kaneko","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218533_bib29","article-title":"A prospective non-randomized clinical study to evaluate the efficacy of intraperitoneal PD-1 monoclonal antibody for end-stage liver cancer patients with ascites: Long-term outcomes","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102206","article-title":"Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218533_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10147-025-02930-y","article-title":"Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer","volume":"31","author":"Wang","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101251","article-title":"Bispecific antibodies for the treatment of hematologic malignancies: the magic is T-cell redirection","volume":"69","author":"Shouse","year":"2025","journal-title":"Blood Rev."},{"key":"10.1016\/j.canlet.2026.218533_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ijc.10562","article-title":"Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma","volume":"101","author":"Marme","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib34","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib35","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","article-title":"Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study","volume":"24","author":"Berek","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib36","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib37","first-page":"833","article-title":"A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer","volume":"18","author":"Bokemeyer","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib38","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1634\/theoncologist.2015-0076","article-title":"Outpatient intraperitoneal catumaxomab therapy for malignant ascites related to advanced gynecologic neoplasms","volume":"20","author":"Kurbacher","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218533_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012292","article-title":"Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)","volume":"13","author":"Restle","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"TPS5630-TPS","key":"10.1016\/j.canlet.2026.218533_bib40","article-title":"SynKIR-CAR T cell advanced research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma","volume":"43","author":"Tanyi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib41","doi-asserted-by":"crossref","first-page":"TPS5626","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5626","article-title":"Phase I\/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer","volume":"42","author":"Knisely","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib42","first-page":"99","article-title":"Oncolytic virus as an agent for the treatment of malignant ascites","volume":"24","author":"Liu","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.canlet.2026.218533_bib43","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.ymthe.2024.04.029","article-title":"Oncolytic adenovirus in treating malignant ascites: a phase II trial and longitudinal single-cell study","volume":"32","author":"Zhang","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218533_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e20549","article-title":"Autologous, oncolytic virus-activated killer (VAK) cell therapy to treat malignant pleural and peritoneal effusions","volume":"42","author":"Dong","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e14553","article-title":"Phase I study of oncolytic adenovirus BioTTT001 in patients with peritoneal carcinomatosis","volume":"43","author":"Liu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e14581","article-title":"Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: analyses of two phase 1 studies","volume":"42","author":"Niu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib47","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib48","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218533_bib49","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaoncol.2023.1007","article-title":"Clinical activity of olvimulogene nanivacirepvec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: the nonrandomized phase 2 VIRO-15 clinical trial","volume":"9","author":"Holloway","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071702","article-title":"Ovarian cancer-associated ascites have high proportions of cytokine-responsive CD56bright NK cells","volume":"10","author":"Tonetti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218533_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133362","article-title":"Identification of tissue-resident natural killer and T lymphocytes with anti-tumor properties in ascites of ovarian cancer patients","volume":"15","author":"Bernson","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218533_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015625","article-title":"Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines","volume":"5","author":"Tran","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218533_bib53","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.7150\/jca.83615","article-title":"Tissue resident memory T cells are enriched and dysfunctional in effusion of patients with malignant tumor","volume":"14","author":"Mao","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib54","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1111\/cas.13723","article-title":"PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer","volume":"109","author":"Nakano","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218533_bib55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12885-022-09534-z","article-title":"Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer","volume":"22","author":"Sato","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib56","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fimmu.2017.01482","article-title":"Interleukin 6 present in inflammatory ascites from advanced epithelial ovarian cancer patients promotes tumor necrosis factor receptor 2-Expressing regulatory T cells","volume":"8","author":"Kampan","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib57","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ijc.32990","article-title":"Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites","volume":"147","author":"Gong","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00262-025-04174-1","article-title":"Differentiation and mitochondrial metabolic characteristics of CD8(+) T cells in malignant ascites of epithelial ovarian cancer and their correlation with estrogen signaling","volume":"74","author":"Jiang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218533_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010273","article-title":"Different lipid regulation in ovarian cancer: inhibition of the immune System","volume":"19","author":"Wefers","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218533_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adr4795","article-title":"Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer","volume":"10","author":"Slattery","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030893","article-title":"Amino acid-metabolizing enzymes in advanced high-grade serous ovarian cancer patients: value of ascites as biomarker source and role for IL4I1 and IDO1","volume":"15","author":"Grobben","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218533_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279590","article-title":"Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer","volume":"18","author":"Yoshida-Court","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218533_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1698793","article-title":"Decoding ascitic immunological niches with multi-modal machine learning reveals prognostic and chemoresistant determinants in ovarian cancer","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib64","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1007\/s13277-015-4538-0","article-title":"Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients","volume":"37","author":"Wei","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.canlet.2026.218533_bib65","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ijc.35229","article-title":"Tumor-derived lactic acid promotes acetylation of histone H3K27 and differentiation of IL-10-producing regulatory B cells through direct and indirect signaling pathways","volume":"156","author":"Muraoka","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/0008-5472.CAN-18-0981","article-title":"Activation of B-1 cells promotes tumor cell killing in the peritoneal cavity","volume":"79","author":"Haro","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib67","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bjc.6602334","article-title":"Ascitic complement system in ovarian cancer","volume":"92","author":"Bjorge","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib68","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2026.218533_bib69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10120-024-01486-6","article-title":"Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis","volume":"27","author":"Li","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib70","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","article-title":"Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells","volume":"110","author":"Duluc","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218533_bib71","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-14-3373","article-title":"Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer","volume":"75","author":"Moughon","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib72","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.163.11.6251","article-title":"Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells","volume":"163","author":"Loercher","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib73","doi-asserted-by":"crossref","first-page":"76843","DOI":"10.18632\/oncotarget.20164","article-title":"Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cells in ovarian cancer patients","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218533_bib74","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-04-4043","article-title":"Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma","volume":"65","author":"Wei","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib75","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1158\/0008-5472.CAN-04-1272","article-title":"Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer","volume":"64","author":"Curiel","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib76","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-023-36310-9","article-title":"Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis","volume":"14","author":"Huang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218533_bib77","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00262-024-03833-z","article-title":"PD-L1(+) neutrophils induced NETs in malignant ascites is a potential biomarker in HCC","volume":"73","author":"Sun","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218533_bib78","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/jleuko\/qiae166","article-title":"G-CSF induces neutrophil extracellular traps formation and promotes ovarian cancer peritoneal dissemination","volume":"116","author":"Bun","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.canlet.2026.218533_bib79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000135689","article-title":"The local cytokine and chemokine milieu within malignant effusions","volume":"29","author":"Atanackovic","year":"2008","journal-title":"Tumour Biol"},{"key":"10.1016\/j.canlet.2026.218533_bib80","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ejca.2011.03.026","article-title":"Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer","volume":"47","author":"Yigit","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib81","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1245\/s10434-023-14553-6","article-title":"Characterizing the immune environment in peritoneal carcinomatosis: insights for novel immunotherapy strategies","volume":"31","author":"Wagner","year":"2024","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00262-023-03616-y","article-title":"The complex role of IL-10 in malignant ascites: a review","volume":"73","author":"Huang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218533_bib83","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/0008-5472.CAN-10-1496","article-title":"IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer","volume":"71","author":"Lo","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17243925","article-title":"Ovarian cancer ascites enriched for CCL23 reduces macrophage-derived CXCL10 secretion and is associated with poor patient outcomes","volume":"17","author":"Lang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218533_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt369","article-title":"TGF-beta: duality of function between tumor prevention and carcinogenesis","volume":"106","author":"Principe","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2026.218533_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205086","article-title":"TGFbeta signaling in the pancreatic tumor microenvironment","volume":"13","author":"Principe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218533_bib87","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/0008-5472.CAN-15-1293","article-title":"TGFbeta signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis","volume":"76","author":"Principe","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1448041","article-title":"Increased peritoneal TGF-beta1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer","volume":"15","author":"Maas","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104380","article-title":"The difficulty in translating the preclinical success of combined TGFbeta and immune checkpoint inhibition to clinical trial","volume":"86","author":"Metropulos","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2026.218533_bib90","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","article-title":"Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma","volume":"10","author":"Czystowska-Kuzmicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218533_bib91","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1180485","article-title":"Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-kappaB signal pathway","volume":"5","author":"Zhou","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218533_bib92","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40425-018-0452-5","article-title":"Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1","volume":"6","author":"Wen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib93","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.2001095","article-title":"Ovarian cancer ascites inhibits transcriptional activation of NK cells partly through CA125","volume":"208","author":"Fraser","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/onc.2016.206","article-title":"Extracellular purines, purinergic receptors and tumor growth","volume":"36","author":"Di Virgilio","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218533_bib95","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/bjc.2012.468","article-title":"VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2","volume":"107","author":"Gavalas","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib96","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of Myeloid-Derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2016.05.004","article-title":"Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108","volume":"63","author":"Jordan","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib98","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2021.02.002","article-title":"REZOLVE (ANZGOG-1101): a phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","volume":"161","author":"Sjoquist","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib99","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520986664","article-title":"Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites","volume":"49","author":"Kou","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.canlet.2026.218533_bib100","doi-asserted-by":"crossref","first-page":"35262","DOI":"10.18632\/oncotarget.13064","article-title":"Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218533_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib102","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.241828","article-title":"The lymph node at a glance - how spatial organization optimizes the immune response","volume":"133","author":"Grant","year":"2020","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2026.218533_bib103","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1038\/s41388-020-1288-2","article-title":"Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites","volume":"39","author":"Kan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218533_bib104","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1172\/JCI87252","article-title":"Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer","volume":"126","author":"Yin","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218533_bib105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1186\/s12967-025-07162-2","article-title":"Insights into spheroid formation: interaction of ovarian cancer cells with macrophage populations in the tumor microenvironment","volume":"23","author":"Pisano","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218533_bib106","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu5944","article-title":"Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation","volume":"12","author":"Uno","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218533_bib107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/imr.12748","article-title":"Fibroblastic reticular cells at the nexus of innate and adaptive immune responses","volume":"289","author":"Perez-Shibayama","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218533_bib108","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.it.2021.07.003","article-title":"Communication, construction, and fluid control: Lymphoid organ fibroblastic reticular cell and conduit networks","volume":"42","author":"Acton","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib109","doi-asserted-by":"crossref","first-page":"42262","DOI":"10.18632\/oncotarget.15040","article-title":"Malignant ascites-derived exosomes promote proliferation and induce carcinoma-associated fibroblasts transition in peritoneal mesothelial cells","volume":"8","author":"Wei","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218533_bib110","first-page":"2245","article-title":"Tumor cell-fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer","volume":"44","author":"Han","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218533_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112153","article-title":"Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived COL1A1 and facilitates ovarian cancer metastasis","volume":"394","author":"Li","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2026.218533_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114155","article-title":"Ascites microenvironment conditions the peritoneal pre-metastatic niche to promote the implantation of ovarian tumor spheroids: involvement of fibrinogen\/fibrin and alphaV and alpha5beta1 integrins","volume":"441","author":"Laurent-Issartel","year":"2024","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2026.218533_bib113","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10456-021-09792-8","article-title":"High endothelial venules (HEVs) in immunity, inflammation and cancer","volume":"24","author":"Blanchard","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2026.218533_bib114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fimmu.2017.00045","article-title":"High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function","volume":"8","author":"Ager","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib115","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1182\/blood-2011-07-367409","article-title":"High endothelial venules as traffic control points maintaining lymphocyte population homeostasis in lymph nodes","volume":"118","author":"Mionnet","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218533_bib116","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","article-title":"Markedly elevated levels of vascular endothelial growth factor in malignant ascites","volume":"6","author":"Zebrowski","year":"1999","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib117","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2012.05.002","article-title":"VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5","volume":"127","author":"Herr","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218533_bib118","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-016-0497-3","article-title":"Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?","volume":"15","author":"Bekes","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib119","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1084\/jem.20120150","article-title":"Germinal center B cells govern their own fate via antibody feedback","volume":"210","author":"Zhang","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218533_bib120","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1016\/j.cell.2021.05.028","article-title":"A local regulatory T cell feedback circuit maintains immune homeostasis by pruning self-activated T cells","volume":"184","author":"Wong","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218533_bib121","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature16169","article-title":"Immune homeostasis enforced by co-localized effector and regulatory T cells","volume":"528","author":"Liu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218533_bib122","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41590-023-01540-y","article-title":"Distinct metabolic requirements regulate B cell activation and germinal center responses","volume":"24","author":"Sharma","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib123","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2021.12.012","article-title":"Metabolic adaptation of lymphocytes in immunity and disease","volume":"55","author":"Chapman","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218533_bib124","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13046-023-02798-8","article-title":"Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites","volume":"42","author":"Hrvat","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218533_bib125","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/eji.201242754","article-title":"Pathophysiological hypoxia affects the redox state and IL-2 signalling of human CD4+ T cells and concomitantly impairs survival and proliferation","volume":"43","author":"Gaber","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2026.218533_bib126","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.immuni.2022.07.019","article-title":"Lymphatic migration of unconventional T cells promotes site-specific immunity in distinct lymph nodes","volume":"55","author":"Ataide","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218533_bib127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","article-title":"Structures and mechanisms in the cGAS-STING innate immunity pathway","volume":"53","author":"Zhang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218533_bib128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002195","article-title":"STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218533_bib129","doi-asserted-by":"crossref","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","article-title":"Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden","volume":"114","author":"Stone","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218533_bib130","article-title":"Ferroptosis-Enhanced immunotherapy with an injectable Dextran-Chitosan Hydrogel for the treatment of malignant ascites in hepatocellular carcinoma","volume":"10","author":"Meng","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218533_bib131","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303542","article-title":"Induction of tumor ferroptosis-dependent immunity via an injectable attractive pickering emulsion gel","volume":"35","author":"Dai","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.canlet.2026.218533_bib132","article-title":"IL-15\/IL-15Ralpha-secreting bioengineered adipocytes reactivate NK\/CD8(+) T cells in ovarian and colon cancer ascites","volume":"304","author":"Zhang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2026.218533_bib133","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1060392","article-title":"Hyperthermic intra-peritoneal chemotherapy and anticancer immune response","volume":"5","author":"Zunino","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218533_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72826-w","article-title":"CD8 + T-cells restrict the development of peritoneal metastasis and support the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"14","author":"Roth","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218533_bib135","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1245\/s10434-022-13025-7","article-title":"PD-1 blockade combined with heated intraperitoneal chemotherapy improves outcome in experimental peritoneal metastases from colonic origin in a murine model","volume":"30","author":"Geva","year":"2023","journal-title":"Ann. Surg Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:35:02Z","timestamp":1783175702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":135,"alternative-id":["S030438352600296X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218533","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant ascites as an immune organ and implications for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218533"}}